CDKAL1 and prostate carcinoma: We confirmed the overlapped immunofluorescent signals of CDKAL1 and SALL2 in RMS cells (Figure 4I), as well as melanoma (Figure S6A, Supporting Information), liver cancer (Figure S7A, Supporting Information), prostate cancer (Figure S8A, Supporting Information), and stomach cancer (Figure S9A, Supporting Information).